Mandate

Vinge advised Nextmune in connection with its acquisition of I.C.F. S.r.l and D.R.N. S.r.l.

October 08, 2020 Banking and Finance M&A

Vinge has advised Fidelio Capital and its portfolio company Nextmune, a leading science driven, global specialty pharmaceutical company dedicated to improving health for dogs, cats and horses, in connection with its acquisition of I.C.F. S.r.l and D.R.N. S.r.l.

Related

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026